This is the first clinical trial of an IL-6–targeted therapy in PsA. Clazakizumab may be an effective treatment option for musculoskeletal aspects of PsA, but because of the lack of a dose response in this study, further studies are required to confirm the appropriate dose. The safety profile is consistent with the pharmacology of IL-6 blockade and prior clinical experience with this antibody in rheumatoid arthritis…
Articles tagged with "Interleukin"
NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…
New research clarifies the role of fibroblasts in chronic lung disease. (posted Jan. 21)
Researchers have identified a unique population of entheseal resident cells that can be activated by interleukin 23 (IL-23). This finding may be key to understanding how dysregulation of IL-23 results in precise inflammation of the entheses.
Research in the laboratory of John D. Mountz, MD, PhD, is opening up a whole new field of study in rheumatoid arthritis (RA).
Perspectives on selections from the literature
Pierre Miossec, MD, of the department of immunology and rheumatology at the Hospital Eduoard Herriot and professor of clinical immunology of Claude Bernard University, both in Lyon, France, was awarded the Carol Nachman Prize for Rheumatology this May in Wiesbaden, Germany. The award promotes clinical, therapeutic, and experimental studies in rheumatology and is the highest international honor for rheumatology research. Dr. Miossec, a long-time researcher of the role of cytokines in rheumatoid arthritis (RA), was honored for his discoveries of the functions of the T cell–derived cytokine interleukin-17 (IL-17) in this inflammatory disease.
Exploring advances, evaluating what remains to be done
Evolving model has implications for novel therapies
Understanding the genetic basis of errors of the immune system may provide new opportunities for therapy